| Azathioprine |
![]() Last updated: 15/09/2025 |
![]() |
(Also known as: AZA) |
|
|
|
Azathioprine is a pro-drug of 6-mercaptopurine and is used in veterinary medicine as an immunosuppressant | |
|---|---|---|
|
Helps control rheumatoid arthritis, Crohn's disease and inflammatory bowel disease | |
|
Dogs; Ferrets |
| Approval status |
|
Not approved | |
|---|---|---|
|
Not approved |
| Chemical structure |
|
None | |
|---|---|---|
|
C₉H₇N₇O₂S | |
|
CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-] | |
|
- | |
|
LMEKQMALGUDUQG-UHFFFAOYSA-N | |
|
InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13) | |
|
Yes |
| General status |
|
Immune system suppressant; Medicinal drug | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Thiopurine drug | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Azathioprine works via 6-thioguanine to disrupt the making of RNA and DNA by cells | ||||||||||||||
|
[Amidophosphoribosyltransferase, Inhibitor], [Ras-related C3 botulinum toxin substrate 1, Modulator] | ||||||||||||||
|
446-86-6 | ||||||||||||||
|
207-175-4 | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
2265 | ||||||||||||||
|
Immunosuppressants; Other immunosuppressants | ||||||||||||||
|
QL04AX01 | ||||||||||||||
|
No | ||||||||||||||
|
Not approved | ||||||||||||||
|
277.26 | ||||||||||||||
|
- | ||||||||||||||
|
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine | ||||||||||||||
|
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine | ||||||||||||||
|
|
||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Products are pale yellow crystals or a yellowish powder | ||||||||||||||
| Commercial |
|
|
|||
|---|---|---|---|---|
|
Current | |||
|
1956, first synthesised; 1968, first US clinical approval | |||
|
|
|||
|
|
|||
|
Usually administered orally or by injection | |||
|
The production of azathioprine involves a multi-step synthetic pathway that constructs its purine-sulphur-imidazole framework. It begins with the formation of N,N′-dimethyloxalamide by reacting methanamine with diethyl oxalate in the presence of ethylhydroxide at room temperature. This intermediate is then chlorinated using phosphorus pentachloride to yield 5-chloro-1-methyl-1H-imidazole, which undergoes nitration to produce 5-chloro-1-methyl-4-nitro-1H-imidazole. The final step involves coupling this nitroimidazole derivative with 9H-purine-6-thiol, forming azathioprine through a nucleophilic substitution at the sulphur atom. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
|
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
238 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
243 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
No negative impacts identified or anticipated | ||||||||||
| Degradation |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- | ||||||||||
| Soil adsorption and mobility |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
| Fate indices |
|
|
|
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - | |||||||||||||||||||||||||||
| Known metabolites |
None
|
|
| Terrestrial ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
| - | |||||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- |
|
- | - | - | ||||||
|
- | ||||||||||
| Aquatic ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - | ||||||||
|
|
| General |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Azathioprine metabolises to thiouric acid and various methylated and hydroxylated purines, which are excreted via the urine | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
| Health issues |
|
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
IARC Group I - known human carcinogen DNA toxin Possible liver toxin |
||||||||||||||||||||||||||||
| Handling issues |
|
|
|||
|---|---|---|---|---|
|
No information available | |||
|
- | |||
|
- | |||
|
- | |||
|
- | |||
|
- |
|
|
|
|
||
|---|---|---|---|
|
azathioprine | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
| Record last updated: | 15/09/2025 |
| Contact: | aeru@herts.ac.uk |
| Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |
© Copyright University of Hertfordshire, 2006-2026. All Rights Reserved
Your use of this website and its various databases is subject to the terms detailed in the University of Hertfordshire’s copyright and IPR statement that can be found at https://www.herts.ac.uk/about-us/legal. In addition, your use of this website and its various databases is subject to the terms of this additional Copyright Statement and the database Conditions of use document. Unless explicitly stated otherwise, the content of this website and databases are owned and controlled by the University of Hertfordshire. Site content, including its selection and arrangement, is owned by the University of Hertfordshire and is protected by copyright and other laws. Except as otherwise expressly permitted under copyright law or within the database Conditions of Use document, the content of this site may not be copied, reproduced, republished, downloaded, posted, broadcast or transmitted in any way without first obtaining the University of Hertfordshire’s written permission. By using our databases the user is deemed to have agreed to comply with all of the terms and conditions as described above and within all relevant documentation.



